Test your drug on human tumor models.
For human-relevant results.
CanChip builds miniaturized human tumor systems that replace animal testing in oncology — delivering clinically relevant drug response data before Phase I begins.
Tumor-on-Chip • Human-relevant data • 3D microfluidics • Oncology validation • Fraunhofer-certified • No animal testing
Animal models have taken us far.
Human-relevant models can take us further.
Validated across tumor models.
A few examples to get started.
Liver-on-Chip
Validated
~4× higher CYP3A4 expression vs. 2D standard culture
Pancreas-on-Chip
Validated
~5× CA19-9 reduction under combination therapy
CRC-on-Chip
Validated
Strong TYMS suppression + RAC3 downregulation under 5-FU
Prostate-on-Chip
Validated
Up to 66% PSA suppression under enzalutamide — dose-dependent
Validated by science.
Recognized by industry.
2025
Brandenburg Innovation Prize
CanChip GmbH received a special award at the 2025 Brandenburg Innovation Prize. The jury recognized our Tumor-on-a-Chip models as an outstanding innovation — an important milestone for our company.
This recognition confirms that our technology is market-relevant and forward-looking, with real potential to transform cancer research.
2024 · Good Health & Wellbeing
Eutech SDG Award
CanChip GmbH won first place in the SDG 3 category of the renowned EUTECH SDG Awards 2024, which recognize initiatives making a significant contribution to achieving the United Nations Sustainable Development Goals (SDGs). This award honors CanChip’s innovative approach to improving global health and wellbeing through its pioneering Cancer-on-Chip research. These technologies enable groundbreaking solutions for effective drug testing and cancer therapies.
The SDG Awards, hosted by the SDG Alliance of the European Chamber of Technology, honor projects that demonstrate strong commitment to sustainable development and social impact. Winning this award underscores CanChip’s commitment to better health outcomes and to advancing technological progress that benefits society worldwide.
Certified by
Fraunhofer IAP
We’re presenting the results of our latest collaboration with the Fraunhofer Institute for Applied Polymer Research (IAP), investigating drug absorption in 3D-printed microfluidic chips.
The chips’ performance was tested using 5-fluorouracil (5FU) as a model substance, with absorption properties measured over 72 hours using UV-Vis spectroscopy. These results confirm the precision and reliability of our chips for controlled drug absorption studies and highlight their potential for pharmaceutical research applications. This partnership reflects our commitment to quality and innovation in microfluidic technology. Stay tuned as we continue pushing the boundaries in this field.
2025
KfW Award Gründen 2025 – Landessieger Brandenburg
We are very pleased to announce that CanChip GmbH was named regional winner for Brandenburg in the KfW Award Gründen 2025. Our Tumor-on-a-Chip technology convinced the jury, winning us the €1,000 prize.
This award confirms that our mission — replacing animal testing in cancer research with patient-relevant, ethical, and innovative solutions — is relevant not only scientifically but also socially and economically.
Ready to test your compound on human tumor tissue?
Tell us your indication — we respond with a study concept within 48 hours.